Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of IPV-Al SSI vs IPV SSI in Infants
NCT03032419Phase 3Completed
- Sponsor
- Statens Serum Institut
- Start
- Feb 2017
- Primary completion
- Sep 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Picovax in poliomyelitis (2 arms), sponsored by Statens Serum Institut. Primary endpoint: Seroconversion for poliovirus type 1, 2 and 3. Started Feb 2017; status: completed.
02
Drugs
Picovax
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT03032419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03032419.